Pegvisomant-primed GH stimulation test

Clinical Endocrinology

Volumn 68, Issue 6, 2008, Pages 951-956

  Radetti, Giorgio ^a   Wu, Zida ^b   Elsedfy, Heba H ^c   El Kholy, Mohamed ^a   Bozzola, Mauro ^d   Strasburger, Christian J ^b  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LEVODOPA; LEVOTHYROXINE; PEGVISOMANT; SOMATOMEDIN C;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; SHORT STATURE;

EID: 43949126891     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03132.x     Document Type: Article

References (26)

1. 1 Tassoni, P., Cacciari, E., Cau, M., Colli, C., Tosi, M., Zucchini, S., Cicognani, A., Pirazzoli, P., Salardi, S. & Balsamo, A. (1990) Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. Journal of Clinical Endocrinology and Metabolism, 71, 230–234.
2. 2 Carel, J.C., Tresca, J.P., Letrait, M., Chaussain, J.L., Lebouc, Y., Job, J.C. & Coste, J. (1997) Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a population register‐based study. Journal of Clinical Endocrinology and Metabolism, 82, 2117–2121.
3. 3 Ghigo, E., Bellone, J., Amaretti, G., Bellone, S., Loche, S., Cappa, M., Bartolotta, E., Dammacco, F. & Camanni, F. (1996) Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. Journal of Clinical Endocrinology and Metabolism, 81, 3323–3327.
4. 4 Maghnie, M., Valtorta, A., Moretta, A., Larizza, D., Preti, P., Palladini, G., Calcante, S. & Severi, F. (1993) Diagnosis of growth hormone deficiency: the value of short term hypocaloric diet. Journal of Clinical Endocrinology and Metabolism, 77, 1372–1378.
5. 5 Mauras, N., Walton, P., Nicar, M., Welch, S. & Rogol, A. (2000) Growth hormone stimulation testing in both short and normal statured children: use of an immunofunctional assay. Pediatric Research, 48, 614–418.
6. 6 Ho, K.Y., Veldhuis, J.D., Johnson, M.L., Furlanetto, R., Evans, W.S., Alberti, K.G. & Thorner, M.O. (1988) Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. Journal of Clinical Investigation, 81, 968–975.
7. 7 Hartman, M.L., Veldhuis, J.D., Johnson, M.L., Lee, M.M., Alberti, K.G., Samojlik, E. & Thorner, M.O. (1992) Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two‐day fast in normal men. Journal of Clinical Endocrinology and Metabolism, 74, 757–765.
8. 8 Thissen, J.P., Ketelslegers, J.M. & Underwood, L.E. (1994) Nutritional regulation of the insulin‐like growth factors. Endocrine Reviews, 15, 80–101.
9. 9 Berelowitz, M., Szabo, M., Frohman, L.A., Firestone, S. & Hintz, R.L. (1981) Somatomedin‐C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science, 212, 1279–1281.
10. 10 Abe, H., Molitch, M.E., Van Wyk, J.J. & Underwood, L.E. (1983) Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology, 113, 1319–1324.
11. 11 Tannenbaum, G.S., Guyda, H.J. & Posner, B.I. (1983) Insulin‐like growth factors: a role in growth hormone negative feedback and body weight regulation via brain. Science, 220, 77–79.
12. 12 Ceda, G.P., Davis, R.G., Rosenfeld, R.G. & Hoffman, A.R. (1987) The growth hormone (GH)‐releasing hormone (GHRH)–GH–somatomedin axis: evidence for rapid inhibition of GHRH‐elicited GH release by insulin‐like growth factors I and II. Endocrinology, 120, 1658–1662.
13. 13 Colao, A., Pivonello, R., Auriemma, R.S., De Martino, M.C., Bidlingmaier, M., Briganti, F., Tortora, F., Burman, P., Kourides, I.A., Strasburger, C.J. & Lombardi, G. (2006) Efficacy of 12‐month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long‐term, high‐dose somatostatin analog treatment: effect on IGF‐I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology, 154, 467–477.
14. 14 Clemmons, D.R., Chihara, K., Freda, P.U., Ho, K.K., Klibanski, A., Melmed, S., Shalet, S.M., Strasburger, C.J., Trainer, P.J. & Thorner, M.O. (2003) Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. Journal of Clinical Endocrinology and Metabolism, 88, 4759–4767.
15. 15 Trainer, P.J., Drake, W.M., Katznelson, L., Freda, P.U., Herman‐Bonert, V., Van Der Lely, A.J., Dimaraki, E.V., Stewart, P.M., Friend, K.E., Vance, M.L., Besser, G.M., Scarlett, J.A., Thorner, M.O., Parkinson, C., Klibanski, A., Powell, J.S., Barkan, A.L., Sheppard, M.C., Malsonado, M., Rose, D.R., Clemmons, D.R., Johannsson, G., Bengtsson, B.A., Stavrou, S., Kleinberg, D.L., Cook, D.M., Phillips, L.S., Bidlingmaier, M., Strasburger, C.J., Hackett, S., Zib, K., Bennett, W.F. & Davis, R.J. (2000) Treatment of acromegaly with the growth hormone‐receptor antagonist pegvisomant. New England Journal of Medicine, 342, 1171–1177.
16. 16 Veldhuis, J.D., Bidlingmaier, M., Anderson, S.M., Evans, W.S., Wu, Z. & Strasburger, C.J. (2002) Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. Journal of Clinical Endocrinology and Metabolism, 87, 5737–5745.
17. 17 Tanner, J.M., Whitehouse, R.H. & Takaishi, M. (1966) Standards from birth to maturity for height, weight, height velocity and weight velocity: British children. Archives of Disease in Childhood, 41, 613–635.
18. 18 Greulich, W.W. & Pyle, S.L. (1969) Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd edn. Stanford University Press, Stanford, CA.
19. 19 Rolland‐Cachera, M.F., Cole, T.J., Sempé, M., Tichet, J., Rossignol, C. & Charraud, A. (1991) Body mass index variations: centile from birth to 87 years. European Journal of Clinical Nutrition, 45, 13–21.
20. 20 Thorner, M.O., Strasburger, C.J., Wu, Z., Straume, M., Bidlingmaier, M., Pezzoli, S.S., Zib, K., Scarlett, J.C. & Bennett, W.F. (1999) Growth hormone (GH) receptor blockade with a PEG‐modified GH (B2036‐PEG) lowers serum insulin‐like growth factor‐I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology and Metabolism, 84, 2098–2103.
21. 21 Elmlinger, M.W., Kuhnel, W., Weber, M.M. & Ranke, M.B. (2004) Reference ranges for two automated chemiluminescent assays for serum insulin‐like growth factor I (IGF‐I) and IGF‐binding protein 3 (IGFBP‐3). Clinical Chemistry and Laboratory Medicine, 42, 654–664.
22. 22 Radetti, G., Buzi, F., Cassar, W., Paganini, C., Stacul, E. & Maghnie, M. (2003) Growth hormone secretory pattern and response to treatment in children with short stature followed to adult height. Clinical Endocrinology, 59, 27–33.
23. 23 Rose, S.R., Ross, J.L., Uriarte, M., Barnes, K.M., Cassorla, F.G. & Cutler, G.B. (1988) The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. New England Journal of Medicine, 319, 201–207.
24. 24 Muller, E.E., Locatelli, V., Ghigo, E., Cella, S.G., Loche, S., Pintor, C. & Camanni, F. (1991) Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications. Drugs, 41, 161–177.
25. 25 Muller, E.E., Locatelli, V. & Cocchi, D. (1999) Neuroendocrine control of growth hormone secretion. Physiological Reviews, 79, 511–607.
26. 26 Ranke, M.B., Schweizer, R., Lindberg, A., Price, D.A., Reiter, E.O., Albertsson‐Wikland, K. & Darendeliler, F. (2004) Insulin‐like growth factors as diagnostic tools in growth hormone deficiency during childhood and adolescence: the KIGS experience. Hormone Research, 62, 17–25.